Original Article

Descriptive Epidemiology of Hepatitis C Virus Among Male Heroin Abusers in Taiwan

Authors: Kuan-Fu Liao, MD, Chen-Yuang Peng, MD, PHD, Shih-Wei Lai, MD, Wu-Long Chang, MS, Nan-Yung Hsu, MD, MS

Abstract

Background:The purpose of this study was to explore the epidemiology of hepatitis C virus (HCV) infection and to determine the risk factors for HCV infection among heroin abusers in Taiwan. Methods:This was a cross-sectional study. From November 2004 to February 2005, 577 subjects, including 423 subjects (73.3%) using injectable heroin and 154 subjects (26.7%) using smoked heroin from one male prison located in Taiwan, were enrolled in this study. The mean age was 33.3 ± 7.9 years (age range 19–65 years). Anti-HCV antibody was tested. A face-to-face interview focusing on sociodemographic information and risk behaviors was addressed. The t test, χ2 test, and multivariate logistic regression were used. Results:The overall prevalence of anti-HCV antibody positivity was 74.9%, with 89.8% among injecting heroin abusers and 33.8% among smoking heroin abusers (P < 0.0001). The multivariate logistic regression analysis demonstrated that needle sharing was independently related to HCV infection (odds ratio = 5.25, 95% confidence interval = 2.48–11.12). Conclusions:The prevalence of anti-HCV antibody positivity among male injecting drug abusers is high in Taiwan. Needle sharing is identified as a potential risk factor for HCV infection.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Main Causes of Deaths in Taiwan in 2002, Department of Health, Taiwan. Available at:http://www.doh.gov.tw/ufile/Doc/S02/9101-eng.xls. Accessed February 23, 2006.
 
2. Chen DS, Wang JT, Chen PJ, et al. Hepatitis C virus infection in Taiwan. Gastroenterol Jpn1991;26(suppl 3):164–166.
 
3. Tsai JF, Chang WY, Jeng JE, et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993;41:296–300.
 
4. Tai DI, Chen CH, Chang TT, et al. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection. J Gastroenterol Hepatol 2002;17:682–689.
 
5. Chen TZ, Wu JC, Yen FS, et al. Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. J Med Virol1995;46:247–251.
 
6. Li CP, Hwang SJ, Lu CL, et al. Risk factor analysis of patients with chronic hepatitis C in Taiwan.Zhonghua Yi Xue Za Zhi (Taipei) 1996;58:275–280.
 
7. Wang CS, Chang TT, Chou P. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J Clin Epidemiol 1998;51:733–738.
 
8. Chang CJ, Ko YC, Liu HW. Seroepidemiology of hepatitis C virus infection among drug abusers in southern Taiwan. J Formos Med Assoc 1998;97:826–829.
 
9. Sun CA, Chen HC, Lu CF, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999;59:290–296.
 
10. Lee PL, Wang JH, Tung HD, et al. A higher than expected recovery rate from hepatitis C infection amongst adolescents: a community study in a hepatitis C-endemic township in Taiwan. Trans R Soc Trop Med Hyg 2004;98:367–372.
 
11. Wang JT, Wang TH, Lin JT, et al. Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan. J Gastroenterol Hepatol 1995;10:454–458.
 
12. Chang TT, Young KC, Yang YJ, et al. Incidence of post-transfusion hepatitis in Taiwan before and after introduction of anti-HCV testing. Liver 1996;16:201–206.
 
13. Lee SD, Chan CY, Wang YJ, et al. Seroepidemiology of hepatitis C virus infection in Taiwan.Hepatology 1991;13:830–833.
 
14. Samuel MC, Doherty PM, Bulterys M, et al. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001;127:475–484.
 
15. Hallinan R, Byrne A, Amin J, et al. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005;20:1082–1086.
 
16. Lai SW, Ng KC, Li CI. Descriptive analysis of HBsAg and HCV antibody prevalence in patients receiving health checkups: a hospital-based study. Mid Taiwan J Med 2004;9(suppl 1):s64–s69.
 
17. Abraham HD, Degli-Esposti S, Marino L. Seroprevalence of hepatitis C in a sample of middle class substance abusers. J Addict Dis 1999;18:77–87.
 
18. Wada K, Greberman SB, Konuma K, et al. HIV and HCV infection among drug users in Japan.Addiction 1999;94:1063–1069.
 
19. Habib SE, Lovejoy FH, Aspin C. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern. Southeast Asian J Trop Med Public Health 2001;32:823–834.
 
20. Herring BL, Tsui R, Peddada L, et al. Wide range of quasispecies diversity during primary hepatitis C virus infection. J Virol 2005;79:4340–4346.
 
21. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201–1205.
 
22. Ko YC, Ho MS, Chiang TA, et al. Tattooing as a risk of hepatitis C virus infection. J Med Virol1992;38:288–291.